The choice of the most efficacious drug for patients with idiopathic overactive bladder (IOAB) remains challenging.
The aim of this network meta-analysis was to determine the most efficacious oral antimuscarinic or β-adrenoceptor agonist accounting for adverse events for the management of IOAB.